Cytogen Cuts 75 Percent of AxCell Biosciences’ Staff
AxCell Biosciences said last week it had laid off three out of four employees and suspended “certain projects” as its parent, Cytogen, tries to cut costs and focus more on its core R&D. Cytogen said AxCell will continue to develop its signal-transduction pathway database for clinical research and functional proteomics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.